# 22. ELN Symposium with 25. KNL Symposium

**Congress Center Rosengarten, Mannheim, March 3, 2026, 7:30-20:00**

| | **WP sessions 1-6 (Mahler 1)** | **Chairs/Contributors** |
|---|---|---|
| **8:00 - 9:00** | **Session 1: WP17 Biometry and Epidemiology** | **M. Pfirrmann, M.Lauseker** |
| 5‘ | Welcome and outline of the program | M. Pfirrmann |
| 17‘ | Challenges in prognostic modelling to be aware of | M. Pfirrmann |
| 17‘ | Too few or too many? - Prospective sample size calculation in clinical trials | T. Lang |
| 17‘ | Sample size considerations beyond sample size calculations | M. Lauseker |
| 5‘ | Concluding remarks | M. Lauseker |
| 9:00 - 9:15 | Break | |
| **9:15 - 10:15** | **Session 2: WP4 CML 1** | **L. Stenke, A. Hochhaus** |
| 9’+3’ | Mechanisms of secondary resistance to asciminib and consequences on therapy | O. Hantschel |
| 9’+3’ | Prediction of successful TFR with DNA/RNA based traffic light system | K. Machova |
| 9’+3’ | CML therapy with clinical evidence in Japan: JALSG CML212 and N/D-STOP216 | Y. Minami |
| 9’+3’ | ASXL1 mutations in the SUSTRENIM study | S. Soverini |
| 9’+3’ | Survey on CML patients’ needs and goals | P. Ernst |
| 10:15 - 10:30 | Coffee Break | |
| **10:30 - 11:30** | **Session 3: WP4 CML 2** | **Weiming Li, H. Malhotra** |
| 8’ | Cardiovascular toxicities associated with 3G-TKIs: data from China | Qian Jiang |
| 8’ | International project regarding additional cytogenetic aberrations in newly diagnosed CML patients | Jiri Mayer |
| 8’ | Outcome after short exposure to tyrosine kinase inhibitors in pregnant women with CML | Yingling Zu |
| 8‘ | Additional genomic abnormalities in CP-CML - where to from here? | D. Yeung |
| 8’ | Disease progression associated with treatment-free remission in CML | Yunfan Yang |
| 8’ | Survey on the burden of TKI intolerance in Chinese CML patients | Weiming Li |
| 12‘ | Discussion topics and proposals: how to do better by cooperating | |
| 11:30 - 11:45 | Break | |
| **11:45 - 12:45** | **Session 4: WP9 MPN** | **T. Barbui, M. Griesshammer, A. Vannucchi** |
| | **Novel proposals:** | |
| 10’ | Observational study of mol response in PV treated with ruxolitinib | P. Guglielmelli |
| 10‘ | DM Insight – ML-application to clinical pattern recognition in MPN | M. Marchetti |
| | **Updates:** | |
| 7’ | The ELN pregnancy consensus project (ET) | M. Griesshammer |
| 7’ | ET consensus management project | A. Vannucchi |
| 10’ | Transition from ET to PV: ET2PV study and update of ERNEST-3 | T. Barbui |
| 10’ | MPN-BP: retro-prospective observation study + update ENABLE study | F. Mannelli |
| 7’ | OLIVETTI project | G. Carreño |
| 12:45 - 13:45 | Lunch | |

| | | |
|---|---|---|
| **13:45 - 14:45** | **Session 10: WP8 MDS** | **L. Malcovati, M. Mittelman** |
| 2’ | Introduction | L. Malcovati |
| 15’ | Report EUMDS Registry | |
| | - General update and developments | |
| | - Highlight of the scientific activities | M. Mittelman, L. Malcovati |
| 10’ | Update International MDS guideline development | L. Malcovati |
| 10’ | ELN iMDS Flow Working Group | |
| | - Emerging role of flowcytometry in MDS – towards recommendation for WHO 6th edition | W. Kern |
| 20’ | Research activities of ELN WP8 members | All |
| 3’ | Closure of the meeting | L. Malcovati, M. Mittelman |
| 14:45 - 15:00 | Break | |
| **15:00 - 16.00** | **Session 6: Multiple Myeloma** | **L. Garderet, G. Gahrton** |
| 5’ | Introduction: why a myeloma session? | L. Garderet, G. Gahrton, J. Hernandez |
| 10’ | The history of myeloma research | G. Gahrton |
| | Myeloma research in 2026: what is the role of…? | |
| 20’ | - Should we treat smoldering multiple myeloma? | H. Ludwig |
| 10’ | - ASCT | C. Scheid |
| 10’ | HARMONY project: meta-analysis of MM-patients | J. Hernandez |
| 5’ | Conclusion | L. Garderet, G. Gahrton, J. Hernandez |
| 16:00 - 16:15 | Coffee Break | |

| | | |
|---|---|---|
| | **WP sessions 7-12 (Mahler 2)** | **Chairs/Contributors** |
| **7:30 - 10:15** | **Session 7: RESOLVE 3rd General Assembly** | **M. Heuser** |
| 5’ | Introduction | M. Heuser |
| 25’ | Management: - Finances | M. Heuser, C. Weinhold-Kiefhaber, |
| | - EU reporting | A. Rusznyak |
| | - Next deliverables | |
| | - Project Steering committee | |
| | - Clinical Trial Steering Committee | |
| 30’ | AML trial - AML investigator meeting | S. Kafert-Kasting, M. Heuser |
| 30’ | CLL trial - CLL investigator meeting | S. Kafert-Kasting, L. Scarfó |
| 20’ | eCRF – MARVIN | B. Neuhaus |
| 30’ | MRD laboratory investigator meeting | J. Cloos, A. Rawstron |
| | MRD eCRF logiqsuite | V. Zhou, M. Brandjes |
| 25’ | Pitfalls of the implementation in the NSGCs and solutions | FILO, SZMC, SAL, OSHO, PALG, GIMEMA, HSH |
| 10:15 - 10:30 | Coffee Break | |
| **10:30 - 11:30** | **Session 7: RESOLVE 3rd General Assembly (continued)** | |
| 45’ | Innovation in the RESOLVE trial: | E. Santoro, M. von Bonin, T. van den Hofen, |
| | Digital medicine, MRD automation, ELN-DAVID RWD | J. Cloos, T. Reuvekamp, P. Armeni |
| 10’ | Communication and dissemination strategy | A. Rusznyak |
| 5’ | Conclusion, next steps | M. Heuser |
| 11:30 - 11:45 | Break | |
| **11:45 - 12:45** | **Session 8: WP5 AML 1** | **C. Röllig, G. Huls** |
| 15’ | Generative AI and Synthetic Data for Decision-Making and Trial Designs in AML | J.-N. Eckardt |
| 15’ | The MRD Real World Data Registry | T. Reuvekamp |
| 20’ | The updated ELN Guidelines on AML MRD | M. Heuser |

| | | |
|---|---|---|
| 10’ | Open forum for discussion and future projects | All |
| 12:45 - 13:45 | Lunch | |
| **13:45 - 14:45** | **Session 9: WP5e (emerging therapies) AML 2** | **C. Röllig, G. Huls, G. Martinelli** |
| | IMPACT-AML EU Project | |
| 10’ | Overview and vision | G. Martinelli |
| 10’ | AML neglected cohorts | C. Junghanß |
| 10’ | IMPACT-AML Trial and STREAM registry: updates on accrual and open sites across the EU | C. Zingaretti |
| 10’ | Tambiciclib in Ven+Aza early resistant AML (SURPASS study) | G. Marconi |
| 10’ | Overcoming venetoclax resistance in AML | V. Raimondi |
| 10’ | Open forum for discussion and future projects | All |
| 14:45 - 15:00 | Break | |
| **15:00 - 16:00** | **Session 5: HARMONY Alliance Foundation** | **J.M. Hernández, L. Bullinger** |
| 10’ | Update on Foundation activities | |
| | HAF New Program for Collaboration with Academic Organisations | J.M. Hernández, V. Behan |
| 45’ | Results from ongoing research projects | L. Bullinger |
| | **AML** | |
| | - Unravelling Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated Adult AML | A. Hernández |
| | - MRD as surrogate endpoint for survival in AML | J. Tettero |
| | - Fully unsupervised genomic classification of patients with diagnosed AML via two distinct Hierarchical Dirichlet Mixture models using the HARMONY Platform | A. Turki |
| | - t-AML, a preliminary analysis from the HARMONY Platform Clinical and biologic features of TP53-mutated AML | L. Guarnera |
| | **CML** | |
| | - iCMLf Genomics Project update | T. Ernst |
| 5’ | Roadmap for 2026 | J.M. Hernández |
| 16:00 - 16:15 | Coffee Break | |

| | **WP sessions 13-16 (Mahler 3)** | **Chairs/Contributors** |
|---|---|---|
| **7:30 - 9:00** | **Session 11: WP14 Transplantation** | **D. Niederwieser, N. Kröger, W. Jędrzejczak, T. Ruutu** |
| 15’ | **Information on submitted/published projects** | |
| | Worldwide electronic global transplant registry (GTR): update (analysis, publication, manuscript) | D. Neumann, D. Niederwieser |
| | Help for Ukrainian hematology patients (HUP) – Laboratory establishment, transplant activities | I. Korenks |
| | New Survey manuscript | D. Niederwieser |
| 60’ | **Current projects** | |
| | Waustim maintenance results (manuscript ready) | A. Cowan, D. Niederwieser |
| | Role of induction therapy for outcome after autologous HCT in MM | H. Takamatsu, L. Garderet |
| | Recommandations on maintenance post-HCT | D. Kim, N. Kröger |
| | CGVHD and CAR-T retrospective study | S. Gill, D. Niederwieser |
| | matched unrelated vs. haploidentical donor for allogeneic HCT in patients with acute leukemia with Identical GVHD Prophylaxis – a randomized prospective - European Trial | N. Kröger |
| | Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: | |

| | | |
|---|---|---|
| | a prospective multicenter phase II trial | N. Gagelmann, N. Kröger |
| | Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in AML with FMS-like tyrosine kinase 3 mutations: a German registry analysis highlighting sorafenib | R. Massoud, N. Kröger |
| | Developments in the clinical assessment of VOD/SOS | T. Ruutu |
| | AML R/R | |
| | - STREAM | G. Martinelli |
| | - HCT protocols in the RPCT | D. Niederwieser |
| | - Update on the Russian parallel RPCT | I. Moiseev |
| | GvHD app | D. Neumann |
| | ELN-recommendations for treating CML | D. Niederwieser |
| 15’ | **New projects** | |
| | National and international recognition for HC-donors | W. Jędrzejczak |
| | AI; GvHD recommendations | all |
| | Pediatric registry | all |
| | General discussion how to do better by cooperating | all |
| 9:00 - 9:15 | Break | |
| **9:15 - 10:15** | **Session 12: WP6 ALL** | **S. Chiaretti, D. Hoelzer** |
| 10’ | First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult Ph+ ALL | S. Chiaretti |
| 10’ | Results of The EVOLVE trial for newly diagnosed Ph+ ALL | F. Lang |
| 10’ | Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult R/R B-ALL | A. Rambaldi |
| 10’ | Incorporation of 8Gy TBI into RIC does not improve alloHCT outcomes for high-risk adult ALL: the UK multicentre ALL-RIC impact study | A. Castleton |
| 10’ | The role of genomics in B-lineage ALL | C. Salek |
| 10’ | Age-overriding international consensus on MRD assessment in ALL | M. Brüggemann |
| 10:15 - 10:30 | Coffee Break | |
| **10.30 – 11.30** | **Session 13: WP10 Immunophenotyping** | **M.C. Béné, G. Zini** |
| 20’ | Morphology update on bone marrow digital solutions | G. Zini |
| 20’ | Flow cytometry update for leukemia diagnosis | M. C. Béné |
| 20’ | Flow cytometry update for MRD | A. Dunlop |
| 11:30 - 11:45 | Break | |
| **11:45 - 12:45** | **Session 14: WP11 Cytogenetics** | **I. Summerer, B. Espinet** |
| 20’ | Harmonizing optical genome mapping for cytogenetic diagnostics: an interlaboratory comparison within the Spanish OGM group | A. Puiggros |
| 20’ | Cause or consequence? Genomic complexity in poor prognosis CLL | J. Strefford |
| 20’ | Clinical relevance of cytogenetic classification in borderline cases (AML-defining cytogenetics with <20% blasts and subclonal MECOM-rearrangements) | I. Summerer |
| 12:45 - 13:45 | Lunch | |
| **13:45 - 14:45** | **Session 15: CLL/ERIC** | **P. Ghia** |
| 10‘ | Introduction | P. Ghia |
| 10‘ | New project: Skin lesions in patients with CLL treated with targeted therapies | A. Wolska-Washer |
| | **Updates on ongoing projects** | |
| 5‘ | Clonal Relationship in Richter Transformation | T. Chatzikonstantinou |
| 5‘ | Effectiveness and safety of I+V treatment in patients with CLL | T. Chatzikonstantinou |
| 10‘ | TP53 aberrations in patients treated with targeted agents | S. Iyengar |

| | | |
|---|---|---|
| 5‘ | Outcomes of patients belonging to subset#2 and having received 1L treatment | T. Chatzikonstantinou |
| 10‘ | RESOLVE trial | A. Rawstron |
| 5‘ | Conclusion | P. Ghia |
| 14:45 - 15:00 | Break | |
| **15:00 - 16:00** | **Session 16: WP12/13 MRD/NGS** | **N.C.P. Cross, C. Thiede, T. Haferlach** |
| 22’ | Long-Read Sequencing in onco-hematology: current challenges and emerging opportunities | N. Bartalucci |
| 22’ | The application of single-cell sequencing to improve our understanding of hematological neoplasms | W. Walter |
| 15’ | ELN myeloid panel | C. Thiede |
| **12:45 – 13:45** | **Poster viewing (Foyer, Poster walks 13:00 -13:45)** | R.P. Gale, H. Malhotra |
| | **SC Meetings (Seminarraum 3.9, separate invitations)** | |
| 16:00 - 16:15 | Coffee Break | |

## Plenary Sessions (Mahler1)

| | | |
|---|---|---|
| **16:15 - 17:30** | **Session 17: General Assembly and Summary reports** | **R. Hehlmann, D. Hoelzer** |
| 20’ | General Assembly | R. Hehlmann |
| 3’ | WP5 (AML 1) | G. Huls |
| 3’ | WP5e (AML 2) | C. Röllig |
| 3’ | HARMONY | J.M. Hernández |
| 3’ | WP8 (MDS) | L. Malcovati |
| 3’ | WP17 (Statistics) | M. Pfirrmann |
| 3’ | WP4 (CML 1) | A. Hochhaus |
| 3’ | WP4 (CML 2) | W. Li |
| 3’ | WP9 (MPN) | A. Vannucchi |
| 3’ | WP6 (ALL) | S. Chiaretti |
| 3’ | WP11 (Cytogenetics) | I. Summerer |
| 3’ | WP10 (Immunophenotyping) | M. Béné |
| 3’ | WP7 (CLL) | P. Ghia |
| 3’ | WP12/13 (MRD, NGS) | N.C.P. Cross |
| 3’ | Session 17 General Assembly RESOLVE | M. Heuser |
| 3’ | WP14 (Transplantation) | D. Niederwieser |
| 3’ | Multiple Myeloma | L. Garderet |
| **17:30** | **Group photo** | |
| 17:30 - 18:00 | Break | |
| **18:00 - 20:00** | **Session 19: Poster Prize, Keynote Lectures, Special Lecture** | **R. Hehlmann, D. Hoelzer** |
| 10‘ | Presentation of Poster Prize | H. Malhotra, R. Gale |
| 20‘ | The prospects of cure of CML | D. Ross, Adelaide |
| 20‘ | How to manage leukemia in an embattled country | A. Ibrahim, Beirut |
| 20‘ | The 2025 ELN Recommendations for treating CML | J. Apperley, London |
| 20‘ | Special Lecture: Promoting ELN with a new journal on *„Translational Leukemia Research and Therapy“* | |
| | What to consider when starting a new journal | R. Gale |
| 10‘ | Questions | |
| **20:00** | **Working dinner in the foyer** | |